RU93005194A - METHOD OF INHIBITION AND PREVENTION OF THE EMERGENCE OF VASCULAR PHENOMENA BETA KARABETIN and VITAMIN E, PHARMACEUTICAL COMPOSITION COMPOSITION FROM BETA KAROTINA AND VITAMIN E, PHARMACEUTICAL CENTURIAL PICTURES CENTURY PAGE - Google Patents

METHOD OF INHIBITION AND PREVENTION OF THE EMERGENCE OF VASCULAR PHENOMENA BETA KARABETIN and VITAMIN E, PHARMACEUTICAL COMPOSITION COMPOSITION FROM BETA KAROTINA AND VITAMIN E, PHARMACEUTICAL CENTURIAL PICTURES CENTURY PAGE

Info

Publication number
RU93005194A
RU93005194A RU93005194/14A RU93005194A RU93005194A RU 93005194 A RU93005194 A RU 93005194A RU 93005194/14 A RU93005194/14 A RU 93005194/14A RU 93005194 A RU93005194 A RU 93005194A RU 93005194 A RU93005194 A RU 93005194A
Authority
RU
Russia
Prior art keywords
beta
vitamin
pharmaceutical
composition
karotina
Prior art date
Application number
RU93005194/14A
Other languages
Russian (ru)
Other versions
RU2126679C1 (en
Inventor
Х.Хеннекенс Чарльз
Original Assignee
Бригхэм энд Уименз Хоспитал
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бригхэм энд Уименз Хоспитал filed Critical Бригхэм энд Уименз Хоспитал
Publication of RU93005194A publication Critical patent/RU93005194A/en
Application granted granted Critical
Publication of RU2126679C1 publication Critical patent/RU2126679C1/en

Links

Claims (1)

Настоящее изобретение относится к способу ингибирования возникновения основного сосудистого явления у субъекта, для чего субъекту вводят бета-каротин и/или витамин Е, по одному или в сочетании. Бета-каротин и/или витамин Е вводят таким образом, что в результате снижается опасность для субъекта возникновения основного сосудистого явления. В другом предпочтительном варианте особенно эффективным является бета-каротин в сочетании с аспирином. Кроме того, изобретение включает фармацевтические композиции, состоящие из бета-каротина в сочетании с витамином Е.The present invention relates to a method of inhibiting the occurrence of a major vascular phenomenon in a subject, for which beta-carotene and / or vitamin E are administered to the subject, alone or in combination. Beta-carotene and / or vitamin E are administered in such a way that, as a result, the risk to the subject of the occurrence of the underlying vascular phenomenon is reduced. In another preferred embodiment, beta-carotene in combination with aspirin is particularly effective. In addition, the invention includes pharmaceutical compositions consisting of beta-carotene in combination with vitamin E.
RU93005194A 1990-10-01 1991-09-27 Method of inhibition and prophylaxis of vascular symptoms rising by beta-carotene and vitamin e, a pharmaceutical composition consisting of beta-carotene and vitamin e, a pharmaceutical composition consisting of beta-carotene and aspirin RU2126679C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59202490A 1990-10-01 1990-10-01
US07/592024 1990-10-01
US07/592,024 1990-10-01

Publications (2)

Publication Number Publication Date
RU93005194A true RU93005194A (en) 1995-11-20
RU2126679C1 RU2126679C1 (en) 1999-02-27

Family

ID=24368959

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93005194A RU2126679C1 (en) 1990-10-01 1991-09-27 Method of inhibition and prophylaxis of vascular symptoms rising by beta-carotene and vitamin e, a pharmaceutical composition consisting of beta-carotene and vitamin e, a pharmaceutical composition consisting of beta-carotene and aspirin

Country Status (12)

Country Link
US (1) US5871766A (en)
EP (1) EP0551427A4 (en)
JP (1) JPH06501695A (en)
KR (1) KR19980703596A (en)
AU (1) AU660630B2 (en)
BG (1) BG97678A (en)
BR (1) BR9106938A (en)
CA (1) CA2093008A1 (en)
HU (1) HUT64837A (en)
MC (1) MC2309A1 (en)
RU (1) RU2126679C1 (en)
WO (1) WO1992005780A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61197774A (en) * 1985-02-27 1986-09-02 Sanden Corp Valve plate for coolant compressor
CA2061477A1 (en) * 1991-03-25 1992-09-26 Lawrence J. Daher Analgesic composition containing beta-carotene
DK0689426T3 (en) * 1993-03-22 2000-10-30 Cognis Australia Pty Ltd Therapeutic agent for the treatment of melanomas
AU700689B2 (en) * 1993-03-22 1999-01-14 Betatene Pty Ltd Therapeutic agent for the treatment of melanomas
JPH08510995A (en) * 1993-03-22 1996-11-19 ベータティーン・リミテッド Water dispersible therapeutic compound
US20040180865A1 (en) * 1993-06-04 2004-09-16 Jeffry W. Kreamer Aspirin and vitamin and/or trace element compositions for the amelioration and treatment of vascular disease
IL110139A0 (en) * 1993-06-28 1994-10-07 Howard Foundation Pharmaceutically-active antioxidants
US6262109B1 (en) 1995-12-22 2001-07-17 Henkel Corporation Methods of preventing and/or treating high serum levels of cholesterol and/or lipids
JP2001522229A (en) * 1997-04-02 2001-11-13 ザ・ジヤクソン・ラボラトリー Antioxidant protein 2, genes and methods of using them
WO1998045241A2 (en) 1997-04-04 1998-10-15 Henkel Corporation Lutein esters having high bioavailability
IL121112A (en) 1997-06-19 2005-11-20 Lycored Natural Prod Ind Ltd Synergistic pharmaceutical or dietary compositionscomprising lycopene and vitamin e for preventing ldl oxidation
WO1998057622A1 (en) * 1997-06-19 1998-12-23 Lycored Natural Products Industries Ltd. Synergistic compositions for lycopene and vitamin e for the prevention of ldl oxidation
US6914073B2 (en) 1999-03-18 2005-07-05 Bristol Myers Squibb Company Vitamin formulation for cardiovascular health
EP1036510B1 (en) * 1999-03-18 2004-01-07 Bristol-Myers Squibb Company Vitamin formulation for cardiovascular health
US6805880B1 (en) * 1999-08-20 2004-10-19 Ferrosan A/S Pharmaceutical delivery system for vitamin C and vitamin E and use of a combination of vitamin C and E for preventing or treating conditions involving oxidative stress
US6582721B1 (en) 1999-09-17 2003-06-24 Alcon, Inc. Stable carotene-xanthophyll beadlet compositions and methods of use
US20030104090A1 (en) * 2000-05-05 2003-06-05 Levy Pedro E. Supplements containing annatto extracts and carotenoids and methods for using the same
US7691406B2 (en) * 2000-10-27 2010-04-06 ZeaVision LLC. Zeaxanthin formulations for human ingestion
EP1273297A1 (en) * 2001-07-06 2003-01-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Vitamin E for the treatment of diseases in which the binding of the transcription factor NF-KB and/or AP-1 to promoter target sites has a beneficial effect (eg AIDS, cardiac infarction)
GB2380481B (en) * 2001-08-22 2003-12-03 Cambridge Theranostics Ltd Means for treatment of atherosclerosis
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7145025B2 (en) * 2002-07-29 2006-12-05 Hawaii Biotech, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US7345091B2 (en) * 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7320997B2 (en) * 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US7763649B2 (en) * 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US7723327B2 (en) * 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
DE10244453A1 (en) * 2002-09-24 2004-04-01 Phenomiques Gmbh Inhibition of the protein kinase C-alpha for the treatment of diseases
US8088363B2 (en) 2002-10-28 2012-01-03 Zeavision Llc Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
US9192586B2 (en) 2003-03-10 2015-11-24 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US20070082066A1 (en) * 2003-05-07 2007-04-12 Gierhart Dennis L Use of zeaxanthin to reduce light hyper-sensitivity, photophobia, and medical conditions relating to light hyper-sensitivity
US7941211B2 (en) * 2003-11-17 2011-05-10 Zeavision, Llc. Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
EP1750723A1 (en) 2004-04-14 2007-02-14 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US7351424B2 (en) * 2004-07-22 2008-04-01 Bio Lut S.A. De C.V. Enhanced purity trans-lutein-ester compositions and methods of making same
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
US20060167319A1 (en) * 2004-10-01 2006-07-27 Lockwood Samuel F Methods for the synthesis of unsaturated ketone intermediates useful for the synthesis of carotenoids
US20070065487A1 (en) * 2005-09-21 2007-03-22 Bio Lut S.A. De C.V. Trans-lutein xantophyll ester of high purity and high bioavailability in micellar solution and a process for the preparation thereof
US20070135521A1 (en) * 2005-12-14 2007-06-14 Yamaha Hatsudoki Kabushiki Kaisha Agent for Preventing Metabolic Syndrome
US7282225B1 (en) 2006-09-27 2007-10-16 Occular Technologies, Inc. Composition and methods for improving retinal health
AU2014285095A1 (en) * 2013-07-03 2016-02-25 Barrie Tan CoQ10 (ubiquinone, ubiquinol), vitamin A (retinoic acid, retinol), vitamin E (tocotrienol, tocopherol) and methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853993A (en) * 1973-05-01 1974-12-10 Univ Virginia Process for increasing oxygen diffusivity and method for treating atherosclerosis
JPS6053031B2 (en) * 1978-03-31 1985-11-22 武田薬品工業株式会社 Spiro compounds and their production methods
US4491574A (en) * 1983-03-02 1985-01-01 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Reduction of high dose aspirin toxicity by dietary vitamin A
ATE122885T1 (en) * 1984-01-28 1995-06-15 Roshdy Ismail AGENTS FOR THE TREATMENT OF HEART DISEASES.
US5346488A (en) * 1985-04-08 1994-09-13 The General Hospital Corporation Laser-induced ablation of atherosclerotic plaque
EP0204987B1 (en) * 1985-05-15 1991-11-21 Roshdy Dr. Ismail Medicine containing vitamin e for improving the properties of blood
US5057494A (en) * 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
JP2619491B2 (en) * 1988-08-11 1997-06-11 サントリー株式会社 Astaxanthin-containing composition
CA2011651A1 (en) * 1989-03-08 1990-09-08 Gerald Shklar Composition and method for inducing tumor regression
US5278189A (en) * 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
EP0746202A4 (en) * 1992-01-06 1997-06-25 Health Maintenance Programs Pharmaceutically active antioxydant containing composition and the method of its use to prevent and treat restenosis following angioplasty
US5221668A (en) * 1992-02-26 1993-06-22 Abbott Laboratories Nutritional product for trauma and surgery patients
IL104736A0 (en) * 1992-03-27 1993-06-10 Zeagen Inc Method for producing beta-carotene using a fungal mated culture
US5328845A (en) * 1992-03-27 1994-07-12 Universal Foods Corporation Fungal negative microorganism capable of producing high levels of beta-carotene
EP0643692B1 (en) * 1992-06-04 1999-11-24 Betatene Pty. Ltd. High cis beta-carotene composition
US5310554A (en) * 1992-10-27 1994-05-10 Natural Carotene Corporation High purity beta-carotene
JPH08510995A (en) * 1993-03-22 1996-11-19 ベータティーン・リミテッド Water dispersible therapeutic compound
US5607839A (en) * 1993-07-22 1997-03-04 Nippon Oil Company, Ltd. Bacteria belonging to new genus process for production of carotenoids using same
US5589468A (en) * 1995-01-13 1996-12-31 Clintec Nutrition Co. Method for providing nutrition to elderly patients

Similar Documents

Publication Publication Date Title
RU93005194A (en) METHOD OF INHIBITION AND PREVENTION OF THE EMERGENCE OF VASCULAR PHENOMENA BETA KARABETIN and VITAMIN E, PHARMACEUTICAL COMPOSITION COMPOSITION FROM BETA KAROTINA AND VITAMIN E, PHARMACEUTICAL CENTURIAL PICTURES CENTURY PAGE
SE9200951D0 (en) PHARMACEUTICAL COMPOSITION CONTAINING A DEFINED LIPID SYSTEM
MX9204354A (en) HETERO-CYCLE COMPOUNDS OF 5 MEMBERS, PROCEDURE TO PREPARE THEM AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
RU93048466A (en) APPLICATION OF BENZOTHIOPHENES FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS AND PHARMACEUTICAL COMPOSITION ON THEIR BASIS
CA2065285A1 (en) Antimalarial compositions
DE69413237D1 (en) Plättchenaggregationsinhibitoren
BR9502955A (en) Composition of saccharides with a reduced reducibility and processes to prepare it and to reduce the reducibility of a mixture of saccharides with a reduced reducibility
ITRM910952A0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING GONADATROPINES
MX9201295A (en) DERIVATIVES OF BENZOFURANO, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THAT CONTAIN THEM.
ITMI912237A0 (en) GENESERIN DERIVATIVES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
PH16596A (en) Use of substituted 1,2,5-oxadiazole 2-oxides for combating or preventing diseases of the cardiovascular system
CA2140927A1 (en) Platelet aggregation inhibitors
BE891639A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING GAMMA-BUTYRO-BETAINE FOR THE TREATMENT OF SYNDROMAS CAUSED BY L-CARNITINE DEFICIENCY
ITRM920222A0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING L-CARNITINE AND ACIL-CARNITINE COMBINATION WITH ACE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES.
MX9204395A (en) DERIVATIVES OF 3-DESOXI-MANOSAMINE, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
NO934832D0 (en) Pharmaceutical composition for the prevention or treatment of arterioscerosis
DK0722325T3 (en) Preparation for the treatment or prevention of herpes
MX9203732A (en) R-ENENOMERS OF N-PROPARGIL-1-AMINOINDAN COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
IL100243A0 (en) Pharmaceutical compositions for the treatment of erythrocytic malaria infections
ES2072005T3 (en) USE OF ANALOGS OF 20 (R) -22-OXA-VITAMIN D IN THE PREPARATION OF A MEDICATION FOR THE TREATMENT OF AGING SKIN.
SE8303886L (en) SYNERGETIC ANTIHYPERTENSIVE PHARMACEUTICAL COMPOSITION
RU93058291A (en) ANTIMALERIC SYNERGETIC COMPOSITIONS CONTAINING BENFLUMETOL
KR950010883A (en) Pharmaceutical composition for the treatment and prevention of liver disease
KR950016765A (en) Anti-alcoholic liver disease preventive therapeutic composition comprising aloe, aloe-amodine and aloe-emodine anthrone as active ingredients
NO304409B1 (en) Synergetic antimalarial compositions containing bone flumetol